● neutral
Impact
PhaseFiled/rolling BLA submission
Time to marketIf the BLA submission is completed by end of 2026 and accepted by the FDA, a PDUFA decision on accelerated approval could come in mid-to-late 2027. A confirmatory Phase 3 trial would still be required for full approval.
nomlabofusp Updated Nov 8
What to watch
Watch for completion of the rolling BLA submission (remaining modules expected by end of 2026) and the FDA's subsequent acceptance for filing, which would trigger a PDUFA date assignment. The ICAR 2026 poster presentations on November 12 may provide incremental OLE data but are unlikely to be a major stock-moving event since the data is previously disclosed. The key binary catalyst remains the FDA's accelerated approval decision, likely in 2027.
Bull case
- nomlabofusp is a first-in-class protein replacement therapy that directly addresses the root cause of Friedreich's ataxia (frataxin deficiency), unlike Biogen's Skyclarys which targets downstream inflammation.
- FDA granted Breakthrough Therapy Designation in February 2026, and pre-BLA feedback indicated the existing data package appears capable of supporting accelerated approval.
- Clinical data showed 100% (9/9) of patients achieved and sustained skin frataxin levels over 50% of healthy volunteer mean at 1 year, comparable to asymptomatic carriers.
Bear case
- Stock has fallen sharply from its 52-week high of $6.42 to $2.39, reflecting execution concerns. Several large institutional holders trimmed or exited in Q2 2026, including Millennium Management (-63%), Point72 (-87%), Morgan Stanley (-79%), and Renaissance Technologies (-60%).
- The BLA seeks accelerated approval based on a surrogate endpoint (frataxin levels); a confirmatory Phase 3 trial is still required, creating execution risk for full approval and commercial launch.
- Biogen's Skyclarys (omaveloxolone) is already approved and marketed for Friedreich's ataxia, giving it a first-mover advantage in a small patient population.